Jochem N. Van Der Voort Van Zyp

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 91 publications

How to focal boost in prostate cancer radiotherapy: ESTRO clinical practice consensus recommendations.

How to focal boost in prostate cancer radiotherapy: ESTRO clinical practice consensus recommendations.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: May 27, 2026

Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis.

Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis.

Journal: JAMA oncology

Published: April 30, 2026

Diffusion weighted MRI-based hypoxic fraction as a prognostic factor in the FLAME trial prostate cancer cohort.

Diffusion weighted MRI-based hypoxic fraction as a prognostic factor in the FLAME trial prostate cancer cohort.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: January 27, 2026

Discrepancies Between Global Consensus and Local Implementation in the Management of Advanced Prostate Cancer.

Discrepancies Between Global Consensus and Local Implementation in the Management of Advanced Prostate Cancer.

Journal: European urology open science

Published: December 23, 2025

Learning from every patient: the 'outpatient innovation clinic'.

Learning from every patient: the 'outpatient innovation clinic'.

Journal: Journal of clinical epidemiology

Published: November 17, 2025

Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study.

Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study.

Journal: The Lancet. Oncology

Published: September 21, 2025

Two-fraction Ultrahypofractionated Radiotherapy with focal BOost for intermediate-risk, localized prostate cancer (TURBO): study protocol of a phase II, randomized controlled clinical trial.

Two-fraction Ultrahypofractionated Radiotherapy with focal BOost for intermediate-risk, localized prostate cancer (TURBO): study protocol of a phase II, randomized controlled clinical trial.

Journal: Trials

Published: February 05, 2025

Omission of Contralateral Systematic Biopsies in Unilateral Suspicious Prostate Cancer on Magnetic Resonance Imaging: Implications for Radiation Treatment Selection.

Omission of Contralateral Systematic Biopsies in Unilateral Suspicious Prostate Cancer on Magnetic Resonance Imaging: Implications for Radiation Treatment Selection.

Journal: European urology open science

Published: January 10, 2025

Acute toxicity and quality of life after margin reduction using a sub-fractionation workflow for stereotactic radiotherapy of localized prostate cancer on a 1.5 Tesla MR-linac.

Acute toxicity and quality of life after margin reduction using a sub-fractionation workflow for stereotactic radiotherapy of localized prostate cancer on a 1.5 Tesla MR-linac.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: December 12, 2024

An Overview of Patient-reported Outcomes for Men with Prostate Cancer: Results from the PIONEER Consortium.

An Overview of Patient-reported Outcomes for Men with Prostate Cancer: Results from the PIONEER Consortium.

Journal: European urology open science

Published: November 29, 2024

Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial.

Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: August 28, 2024

Dose-volume parameter evaluation of a sub-fractionation workflow for adaptive radiotherapy of prostate cancer patients on a 1.5 T magnetic resonance imaging radiotherapy system.

Dose-volume parameter evaluation of a sub-fractionation workflow for adaptive radiotherapy of prostate cancer patients on a 1.5 T magnetic resonance imaging radiotherapy system.

Journal: Physics and imaging in radiation oncology

Published: May 31, 2024

Showing 1-12 of 91

Last Updated: 09/26/2026